An Efficacy and Safety Study of TheraFill® Versus KOKEN for 3 Months on Nasolabial Folds

Nasolabial Folds Clinical Trial

Official title:

A Randomized, Multicenter, Prospective, Paired Comparison of the Efficacy and Safety of TheraFill® Versus KOKEN for 3 Months on Nasolabial Folds

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01060943
• Other study ID #: 01TRF
• Status: Completed
• Phase: Phase 3
• First received: January 21, 2010
• Last updated: February 1, 2010
• Start date: May 2008
• Est. completion date: January 2009

Study information

• Verified date: February 2010
• Source: Sewon Cellontech Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

• Investigational Device : TheraFill® (Atelocollagen Dermal Filler)

• Title : A Randomized, Multicenter, Prospective and Paired Comparison of the Efficacy and Safety of TheraFill® versus KOKEN for 3months on Nasolabial Folds

• Sites and investigators :

• The Catholic University of Korea. Kangnam St. Mary's Hospital (#505, Banpo-dong, Seocho-gu, SEOUL)

• The Catholic Univ. of Korea Holy Family Hospital (#2, Sosa-dong, Wonmi-gu, Bucheon-si, Gyeonggi-do)

• Objective : To compare the non-inferiority of TheraFill® with KOKEN for evaluation of the efficacy and safety on Nasolabial Folds for 3months

• Clinical Study Method : Seventy-three subjects who agree to voluntarily participate in the clinical study are randomized to treatment with TheraFill (porcine atelocollagen filler) and KOKEN (bovine atelocollagen filler) in the contralateral fold(NFL). The subjects shall regularly visit the hospital 5 times or more and if subjects take touch-up treatments, the number of visit times will be increased. Treatments shall be repeated at 2 weeks intervals, as required, to achieve "Optimal cosmetic result". Outcomes shall be evaluated by blinded investigators, investigators and subjects at 2,4 and 12 weeks after baseline.

• Subjects : The target number of subjects is 62subjects, and 73 subjects are selected in the screening period in consideration of 15% of dropout rate.

Description:

• Evaluation Criteria And Analysis Method :

1. Efficacy - Evaluate total 3 times : 2, 4 and 12 weeks after last injection. In efficacy evaluation data, for difference in WSRS improvement ratio, normality test on the ratio is used, and for the other evaluation variables, statistical hypothesis test is conducted by using t-test, Wilcoxon rank-sum test, Chi-square test, and ANOVA for repeatedly measured data according to the nature of data.

1. Wrinkle Severity Rating System - It is ranged from 1 point (absent) to 5 points (extreme), and WSRS scores are compared baseline(pre-injection period) with every visits.

2. Evaluation of subject's improvement - It is ranged from 1 point (worse) to 5 points (much improved). A degree of improvement to which the subject decides upon every visit is evaluated, compared to the screening period (baseline).

3. Evaluation of investigator's improvement - It is ranged from 1 point (worse) to 5 points (much improved). A degree of improvement to which the investigator decides upon every visit is evaluated, compared to the screening period (baseline).

2. Safety The analysis of safety evaluation data is conducted through descriptive statistics using the causal relationship between outbreak frequency and the devices .

1. Subjective adverse events : Uncomfortable sense after TheraFill® injection

2. Objective adverse events : Investigator shall observe and evaluate adverse events such as edema, redness, tenderness, pain, bruise, itching, nodule and others at injected site after injection

• Evidence : 1. Photographs At screening period, injection, 2, 4 and 12 weeks after injection and upon an adverse event, the photograph results of the front and side shall be attached to the Case Report Form and utilized as objective reference data.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 73
• Est. completion date: January 2009
• Est. primary completion date: January 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

1. Those who agreed to this treatment and signed the Informed Consent Form

2. Those who are 20 years old or more and desire to take correction of nasolabial folds

3. Those who have an intention of refraining from other cosmetic treatment(other filler injection, laser or chemical peeling, Botox injection or wrinkle reduction) during the clinical study period

4. Those whose Wrinkle Severity Rating Scale (WSRS) is more than 2 points at least

Exclusion Criteria:

1. Subjects or their families who currently have or have the history of autoimmune disease or collagen vascular disease

2. Those who had the history of anaphylactic response

3. Those who are sensitive to implant

4. Those who are sensitive to lidocaine or other amide anesthesia

5. Those who are sensitive to porcine protein

6. Those who are sensitive to control device

7. Those who have taken soft tissue augmentation, laser or cosmetic facial surgery to improve the injection area in 6 months before participation in the clinical study

8. Those who are pregnant or lactating, or expect pregnancy

9. Those who have inflammatory skin disease on the injection area

10. Those who are judged by the subinvestigator to be improper for this study due to mental disease etc.

Related Conditions & MeSH terms

• Nasolabial Folds

Intervention

Device:
• KOKEN
atelocollagen filler 1ml pre-filled syringe. 3% atelocollagen is dissolved in PBS. Inject several times every 2 weeks or more weeks. Total amount should be limited up to 25ml per an year.
• Atelocollagen Filler
1ml pre-filled syringe. 3% atelocollagen is dissolved in PBS. Inject several times every 2 weeks or more weeks. Total amount should be limited up to 25ml per an year.

Locations

Country	Name	City	State
Korea, Republic of	Kangnam St.Mary's Hospital of Catholic University	Seoul	Seo-cho

Sponsors (1)

Lead Sponsor	Collaborator
Sewon Cellontech Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy: Wrinkle Severity Rating Scale - Primary endpoint		At screening period, 2, 4 and 12 weeks after last injection
Primary	Efficacy: An assessment of the degree of improvement based on the judgement of patients		At screening period, 2, 4 and 12 weeks after last injection
Primary	Efficacy: An assessment of the degree of improvement based on the judgement of the Investigators		At screening period, 2, 4 and 12 weeks after last injection